INFO: NATAP Recent Hepatitis C & Coinfection Updates

[Guest guest]

NATAP Recent Hepatitis C & Coinfection Updateshttp://www.natap.orgImpact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (HALT-C Study) - (02/12/07) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07) Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/12/07) Short-duration therapy for hepatitis C & RVR: suitable for all? - (02/12/07) Liver Stiffness Measurement Versus Clinicians' Prediction or Both for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C - (02/09/07) Are Noninvasive Liver Fibrosis Tests Ready for Use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C - (02/09/07) Medivir: Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated - (02/09/07) Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development -

(02/09/07) Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/01/07) Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus - (02/01/07) Time-Released Interferon Drug: OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C - (01/30/07) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07) Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study - (01/26/07) New Hepatitis C Culture System for Study of Virus -

(01/24/07) Coley Suspends Development of HCV Toll-Receptor Drug - (01/23/07) Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia - (01/22/07) Diabetes, HCV and Liver Transplanation - (01/22/07) Arrow Therapeutics Selects a

2nd Hepatitis C Clinical Candidate - (01/22/07) Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis - (01/22/07) Noninvasive Markers of Liver Fibrosis - (01/19/07)Fibrosis Progression Rates Double in Coinfected Within 2 Years -

(02/12/07)